Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Bladder Carcinoma, Genitourinary System Neoplasm, Kidney Carcinoma
About this trial
This is an interventional supportive care trial for Bladder Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Aged 18 and over
- Sufficiently fluent in English
- On active treatment receiving systemic therapy (e.g., chemotherapy, immunotherapy, hormonal therapy, etc.) or radiotherapy
- Patients with diagnosis of a genitourinary (GU) cancer (e.g., prostate, kidney, and bladder cancer) who have grade 1 or 2 fatigue based on physician assessment at the time of study entry
- Clinician assessed prognosis of greater than or equal to six months
- Willing and independently able to provide consent
- Receive a pre-screen FACIT-Fatigue score of less than or equal to 30
Exclusion Criteria:
- Severe sleep disorders (e.g. narcolepsy)
- Eye Diseases which limit the ability of light to be processed (e.g. untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or other retinal disorder)
- Severe psychological impairment (e.g., bipolar disorder or manic episodes)
- Current employment in night shift work
- Previous use of light therapy to alleviate fatigue or depressive symptoms
- Secondary cancer diagnosis within the past 5 years
- Plans to travel across meridians during treatment
- Pregnancy
- Currently recovering from previous eye surgery within the past 6 months that causes eye irritation
- Sensitivity to light, epilepsy, or a history of seizures
Sites / Locations
- City of Hope Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Active Comparator
Arm I (BWL)
Arm II (OT)
Arm III (OT, BWL)
Arm IV (Control)
Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses.
Patients undergo 6 occupational therapist-led sessions over 60 minutes each.
Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses and to complete the occupational therapist-led session over 60 minutes.
Patients undergo routine treatment and usual follow up care with their medical oncologist.